Are peptides legal?

Are peptides legal in Türkiye?

Turkish law has no separate category called “peptide”; what is decisive is whether the product is a medicine (preparation) and its licence. Peptides in cosmetic products are subject to cosmetics legislation, and food products such as collagen peptides are subject to food legislation; details are in the What are peptides? guide. This section concerns products with the nature of a medicine.

What does Law No. 1262 say?

The relevant provisions of Law No. 1262 on Pharmaceutical and Medicinal Preparations (1262 sayılı İspençiyari ve Tıbbi Müstahzarlar Kanunu) are as follows: ^[1]

• Article 1: Preparations that must be given by physician prescription are sold only against a prescription, and others without a prescription, only in pharmacies and pharmaceutical warehouses.
• Article 3: Ministry permission must be obtained before domestically produced preparations are placed on the market and before those produced abroad are imported.
• Article 18: An administrative fine is imposed on those who engage in unlawful promotion and sale of preparations; if promotion or sale is done over the internet, the Ministry immediately decides to block access. Promoting and selling a product with a health claim without permission is also subject to an administrative fine.
• Article 19: Those who manufacture unlicensed preparations and those who knowingly sell, offer for sale, or have them sold are punished with imprisonment of one to five years; if the preparation lacks therapeutic qualities or is made from impure substances, the penalty is increased by one third. Those who sell, market, or advertise a product with a claim that it diagnoses or treats diseases, even though it is not a preparation, receive the same penalty. Importing preparations made abroad without a licence for commercial purposes is smuggling.
• Additional Article 4: Those who manufacture preparations by imitating them in a way that reduces their therapeutic quality or harms the health of users, or who knowingly sell them, are punished under the Turkish Penal Code or the relevant laws.
• Additional Article 6: Preparations that are the subject of the misdemeanors in Articles 18 and 19 are seized, and a decision is made to confiscate their ownership to the public.

Additional Article 7 of the Law, on the other hand, provides that the Ministry may permit the bringing in from abroad of preparations without a licence for examination, testing, or personal treatment, provided they do not exceed the amount accepted by the Ministry. ^[1] This provision is a Ministry permission mechanism; it does not mean an unlicensed product can be freely brought in.

Sale of peptides online

Article 24 of Law No. 6197 on Pharmacists and Pharmacies (6197 sayılı Eczacılar ve Eczaneler Hakkında Kanun) provides that medicines cannot be sold on the internet or any other electronic medium and that websites cannot be opened in the name of pharmacists and pharmacies. ^[2] Articles 18 and 19 of Law No. 1262 above separately provide for access blocking in the case of promotion or sale over the internet. ^[1]

Under the Turkish Penal Code

Article 187 of the Turkish Penal Code No. 5237 (5237 sayılı Türk Ceza Kanunu) provides for imprisonment of one to five years and a judicial fine for a person who produces or sells medicines in a way that endangers people’s lives and health; if the offense is committed within the scope of a profession as a physician, pharmacist, or one based on official permission, the penalty is increased by one third. Article 186 punishes those who sell, supply, or possess spoiled or altered medicines in a way that endangers life and health. ^[3] Whether these provisions would apply to a particular peptide product is determined by the courts according to the nature of the product and the specific case.

Does a “for research use” label provide protection?

The legal texts examined (Laws No. 1262 and 6197) contain no exception specific to a “for research use” or “not for human use” label. ^[1] Article 19 of Law No. 1262 also punishes selling and advertising a product with a claim that it treats disease even if it is not a preparation; therefore, what is decisive is not the label but how the product is presented and what it is. The legal nature of a product is determined by the administration and the courts in the specific case. The scientific and practical meaning of the label is in the What is a research peptide? guide.

What is the situation in the European Union and the United Kingdom?

The basic regulation for medicinal products for human use in the EU is Directive 2001/83/EC. Article 1 of the Directive defines a medicinal product in two ways: any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or any substance that may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis. Article 6 states that no medicinal product may be placed on the market of a Member State unless a marketing authorization has been issued by the competent authority of that Member State or through the EU centralized procedure. ^[5] The second limb of the definition defines the product through its pharmacological, immunological, or metabolic action, independent of how it is presented.

In the United Kingdom, the criminal enforcement unit of the medicines authority MHRA announced that in a raid near Northampton on 28 May 2026 it seized about 12,000 doses of unlicensed weight loss medicines and that this was the agency’s largest seizure of such products. According to the MHRA, the premises were used to manufacture, package, and distribute unlicensed weight loss medicines and peptide products, including retatrutide and tirzepatide; two 29-year-old men were arrested on suspicion of offenses under the Human Medicines Regulations 2012. ^[6]

What is the situation in the US?

There are two separate mechanisms in the US. The first concerns the bulk substances that pharmacies may use when compounding drugs for a patient (compounding). The FDA places substances that may present significant safety risks in “category 2” under its interim policy. On the current page dated April 22, 2026, ipamorelin acetate has been in category 2 for 503B facilities since 29 September 2023; BPC-157, CJC-1295, epitalon, GHK-Cu for the injection route, MOTS-c, selank, semax, and TB-500 appear in the table of substances that were previously in category 2 and were withdrawn by the nominators, and the FDA’s safety assessments remain on the same page. ^[7] These lists are not a drug approval. The July 2026 meeting of the FDA advisory committee and its aftermath are described in the BPC-157 and TB-500 guides.

The second is the sale of unlicensed products. In a warning letter dated 24 August 2026, the FDA treated products of an online seller, such as “GLP-3R” (retatrutide), semaglutide, and tesamorelin, as unapproved new drugs. The FDA wrote that although the product labels carried the statements “for research use only” and “not for human consumption,” descriptions on the website showed that these products were presented as drugs for humans, and that the seller sold solvent together with the products for preparing an injectable solution. ^[8]

For athletes: the WADA 2026 list and Türkiye

In WADA’s Prohibited List, valid from 1 January 2026, peptides appear in three sections: ^[9]

• S0 — Non-approved substances: Any pharmacological substance not addressed in other sections of the list and with no current approval by any governmental regulatory health authority for human therapeutic use (including drugs under preclinical or clinical development, discontinued drugs, and substances approved only for veterinary use) is prohibited at all times; the list names BPC-157 as an example.
• S2 — Peptide hormones, growth factors, and related substances: CJC-1295 appears among GHRH analogs, ipamorelin among growth hormone secretagogues (S2.2.4); “thymosin-β4 and its derivatives, e.g., TB-500” appears among growth factors (S2.3).
• S4 — Hormone and metabolic modulators: MOTS-c is among AMPK activators (S4.4.1); insulins and insulin-mimetics are in section S4.4.2.

All of these sections are prohibited at all times, in and out of competition. It does not follow that a substance not named on the list is permitted; the S0 section also covers non-approved substances without naming them.

The national organization authorized to carry out the fight against doping in sport in Türkiye is the Dopingle Mücadele Derneği (Anti-Doping Association) under the Anti-Doping Authority and Cooperation Protocol (Dopingle Mücadele Yetki ve İş Birliği Protokolü) signed with the Ministry of Youth and Sports on 25 May 2026. The Association states that it is also recognized as the sole authorized national organization by the Turkish National Olympic Committee and 64 national sports federations. ^[10]

Are there criminal consequences for athletes?

The consequences of a doping violation are primarily sporting sanctions, and the criminal dimension varies from country to country. For example, Germany’s 2015 Act against Doping in Sport (AntiDopG) prohibits using a prohibited substance in organized sport, for the purpose of gaining a competitive advantage and without medical justification (“self-doping”), and punishes this with up to three years of imprisonment or a fine; this self-doping provision applies only to top-level athletes in the testing pool or those who earn significant income from sport. The same Act also punishes producing, trading, selling, or administering a doping substance to another person; in serious cases such as sale to those under 18 or commission commercially or as part of a gang, the penalty is one to ten years of imprisonment. ^[11] In Türkiye, on the other hand, the provisions of Law No. 1262 above apply to the seller and importer of an unlicensed product.

Are GLP-1 drugs given by prescription?

Semaglutide, liraglutide, and tirzepatide are licensed drugs in Türkiye (details in Semaglutide, Liraglutide, Tirzepatide). In the EU, the product information of Ozempic carries the phrase “medicinal product subject to medical prescription” as the supply condition. ^[12] In Türkiye, the prescription type is not written in the products’ SmPC (Turkish KÜB) or in TİTCK’s licence list; ^[4] Law No. 1262 provides that preparations that must be given by prescription can be sold only against a prescription and in pharmacies. ^[1] Retatrutide, which is at the research stage, is not approved in any country and has no licence in Türkiye; details are in the Retatrutide guide. Off-label use (for example use of a diabetes drug for weight) and counterfeit product warnings are covered in the relevant drug guides.

Summary table

The Türkiye column is based on TİTCK’s list dated October 16, 2026, and the sport column on WADA’s 2026 list. ^{[4] [9]}

Where to go after this guide?

The health risks of unlicensed products are in Peptide side effects, label language in What is a research peptide?, and peptide classes in the Types of peptides guide. This page is not legal advice; for a specific situation, legal assessment is made by a lawyer.